Medical Condition News

RSS

Catalyst Pharmaceutical Partners, NIDA to jointly conduct Phase II(b) trial of CPP-109 for cocaine addiction

Catalyst Pharmaceutical Partners, Inc. announced today that it has signed a definitive Clinical Trial Agreement (CTA) with the National Institute on Drug Abuse (NIDA) to jointly conduct a U.S. Phase II(b) clinical trial evaluating CPP-109, Catalyst's formulation of vigabatrin, for the treatment of cocaine addiction. As part of the CTA, NIDA, under their agreement with Veteran's Administration Cooperative Studies Program, will provide substantial resources for the estimated $10 million trial cost.

15 Apr 2010

BIOTRONIK launches new Reocor external pacemakers following European CE Mark approval

BIOTRONIK SE & Co. KG today announced the European launch after receiving CE Mark approval for its new Reocor external pacemakers, available in two models for dual and single chamber pacing therapy.

15 Apr 2010

Phase IIa clinical trial results of Serdaxin for treatment of MDD

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing potential best in class oncology and central nervous system therapeutics, today announced clinical results with its investigational new drug, Serdaxin®for the treatment of major depressive disorder.

15 Apr 2010

Interim data from Avid's florbetapir "Image-to-Autopsy" Phase III study to be presented

Avid Radiopharmaceuticals, Inc. today announced the presentation of interim data from its landmark florbetapir "Image-to-Autopsy" Phase III study. These data come from the first cohort of subjects in the trial and are the first ever Phase III results for an agent designed to image Alzheimer's disease pathology.

15 Apr 2010

Phase II GAMMAGARD clinical study for Alzheimer's disease: 18-month results announced

Baxter International Inc. and New York-Presbyterian Hospital/Weill Cornell Medical Center today announced results of an 18-month Phase II clinical study of GAMMAGARD LIQUID and GAMMAGARD S/D [Immune Globulin Intravenous (Human)] (marketed as KIOVIG outside of the U.S.) for mild-to-moderate Alzheimer's disease. This marked the first announcement of clinical trial results measuring function and cognition in patients who received uninterrupted GAMMAGARD for a period of 18 months.

From Baxter International Inc. 15 Apr 2010

UCSF: Obesity prevention strategies must start as early as possible

To be a truly comprehensive and successful anti-obesity program, First Lady Michelle Obama's "Let's Move" campaign must include interventions that target pregnant women, infants, and pre-school-age children, UCSF experts say.

15 Apr 2010

ErbB3 program development candidate selection triggers $5M milestone payment to AVEO Pharmaceuticals

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced it has received a $5 million milestone payment from Biogen Idec International GmbH, a subsidiary of Biogen Idec, Inc., for the selection of the first humanized antibody development candidate from its ErbB3 program.

15 Apr 2010

Scientists develop new guidelines to help doctors diagnose brain tumours in children

Scientists at Birmingham Children's Hospital and the Universities of Nottingham and Southampton have developed new guidelines that should help doctors to diagnose brain tumours in children more quickly.

15 Apr 2010

Researchers identify gene that appears to increase risk of Alzheimer's disease

Researchers have identified a gene that appears to increase a person's risk of developing late-onset Alzheimer's disease, the most common type of Alzheimer's disease. The research will be presented as part of the late-breaking science program at the American Academy of Neurology's 62nd Annual Meeting in Toronto, April 10 - 17, 2010.

15 Apr 2010

Enrollment complete in Jennerex' Phase 1 trial of JX-594 IV administration for solid tumors

Jennerex, Inc., a clinical-stage cancer biotherapeutics company, today announced that it has completed patient enrollment in a Phase 1 clinical trial evaluating the intravenous (IV) administration of JX-594, the company's lead product for the treatment of solid tumors. Jennerex expects to report the results from this trial at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in May 2010.

15 Apr 2010

New research indicates exercise-based rehabilitation can benefit heart failure patients

Your heart is an incredible muscle, pumping an estimated 2,000 gallons of blood through about 60,000 million miles of blood vessels — and beating maybe 100,000 times a day, year after year after year.

15 Apr 2010

Molecular biologist awarded 2010 Pancreatic Cancer Action Network - AACR Career Development Award

Molecular biologist Jonathan Brody, Ph.D., assistant professor, Department of Surgery at Jefferson Medical College of Thomas Jefferson University, has been awarded a 2010 Pancreatic Cancer Action Network - American Association of Cancer Research Career Development Award in memory of Skip Viragh.

15 Apr 2010

UnitedHealth partners with Walgreens and YMCA to control diabetes

The New York Times: "The UnitedHealth Group, one of the nation's largest health insurers, is teaming up with the Y.M.C.A. and retail pharmacies to try a new approach to one of the nation's most serious and expensive medical problems: Type 2 Diabetes. Rather than simply continuing to pay ever-higher medical claims to care for its diabetic customers, UnitedHealth is paying the Y.M.C.A. and pharmacists to keep people healthier."

15 Apr 2010

PROP compound linked to obesity and risk of cardiovascular disease

Whether or not you can taste a bitter compound called 6-n-propylthiouracil (or PROP) may help Professor Beverly Tepper identify your risk for becoming obese and/or developing cardiovascular disease.

15 Apr 2010

2010 UCBeyond Scholarship Program launched to help students living with chronic illnesses

UCB Canada Inc. is proud to announce the launch of the 2010 UCBeyond Scholarship Program. During its four-year lifespan, the UCBeyond Scholarship has allocated almost 70 educational bursaries worth close to $350,000.00 CAN to students living with chronic illnesses such as rheumatoid arthritis, Crohn's disease and epilepsy.

15 Apr 2010

Hybridyne Imaging Technologies' ProxiScan gamma camera receives FDA clearance for endocavity imaging

Hybridyne Imaging Technologies, Inc., a developer of compact, high-resolution gamma cameras for the detection of cancer and other abnormalities in the body, announces FDA clearance of ProxiScan. The system can be used in imaging the distribution of radionuclides in the human body using planar imaging techniques. ProxiScan may also be used intra-operatively, on pathological specimens and for endocavity applications if a protective sheath is used.

15 Apr 2010

Epilepsy patients who take Ginkgo products face increased risk of seizures: Report

Restrictions should be placed on the use of Ginkgo biloba - a top-selling herbal remedy - because of growing scientific evidence that Ginkgo may increase the risk of seizures in people with epilepsy and could reduce the effectiveness of anti-seizure drugs, a new report concludes. The article appears in ACS' monthly Journal of Natural Products.

15 Apr 2010

Family support critical for managing patients with chronic health problems

Almost 40 percent of chronically ill older adults in the U.S. live alone, and a majority of those who are married have spouses with at least one chronic illness that can affect their ability to provide support, according to a U-M study published in the journal Chronic Illness.

15 Apr 2010

Americans associate good health with lifestyle behaviors, but overlook key Vital Health measures

The American Society of Anesthesiologists (ASA) today released results from the inaugural Vital Health Report, which demonstrate that Americans associate good health with lifestyle behaviors and habits, but overlook their key Vital Health measures (e.g. cholesterol, body mass index, blood pressure, disease screenings), some of the true indicators of overall health. The report further reveals that Americans believe they know more about their Vital Health than they actually do.

15 Apr 2010

First patient enrolled in Endologix percutaneous EVAR pivotal clinical trial

Endologix, Inc., developer of minimally invasive treatments for aortic disorders, announced today that the first patient has been enrolled in the Company's prospective, multicenter, randomized clinical trial for a bilateral percutaneous approach to endovascular abdominal aortic aneurysm repair.

15 Apr 2010

Medical Condition News

Catalyst Pharmaceutical Partners, NIDA to jointly conduct Phase II(b) trial of CPP-109 for cocaine addiction

BIOTRONIK launches new Reocor external pacemakers following European CE Mark approval

Phase IIa clinical trial results of Serdaxin for treatment of MDD

Interim data from Avid's florbetapir "Image-to-Autopsy" Phase III study to be presented

Phase II GAMMAGARD clinical study for Alzheimer's disease: 18-month results announced

UCSF: Obesity prevention strategies must start as early as possible

ErbB3 program development candidate selection triggers $5M milestone payment to AVEO Pharmaceuticals

Scientists develop new guidelines to help doctors diagnose brain tumours in children

Researchers identify gene that appears to increase risk of Alzheimer's disease

Enrollment complete in Jennerex' Phase 1 trial of JX-594 IV administration for solid tumors

New research indicates exercise-based rehabilitation can benefit heart failure patients

Molecular biologist awarded 2010 Pancreatic Cancer Action Network - AACR Career Development Award

UnitedHealth partners with Walgreens and YMCA to control diabetes

PROP compound linked to obesity and risk of cardiovascular disease

2010 UCBeyond Scholarship Program launched to help students living with chronic illnesses

Hybridyne Imaging Technologies' ProxiScan gamma camera receives FDA clearance for endocavity imaging

Epilepsy patients who take Ginkgo products face increased risk of seizures: Report

Family support critical for managing patients with chronic health problems

Americans associate good health with lifestyle behaviors, but overlook key Vital Health measures

First patient enrolled in Endologix percutaneous EVAR pivotal clinical trial

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Latest News